Company & Sponsor Intelligence

argenx

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting3

Completed0

Countries1

Therapeutic footprint

neuromuscularother_neurology

Indexed studies

NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
other_neurology · United StatesPHASE3

NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
neuromuscular · United StatesPHASE3

NCT06392386A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
neuromuscular · United StatesPHASE2, PHASE3

Intelligence layer updated: 2026-10-29 23:42:44.865458+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →